Skip to content

Near INfrared Spectroscopy in Aortic valvE ReplacemenT

Near Infrared Spectroscopy in Aortic Valve Replacement

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01251328
Acronym
INSERT
Enrollment
62
Registered
2010-12-01
Start date
2010-12-31
Completion date
2012-04-30
Last updated
2015-02-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aortic Valve Stenosis, Eligibility for Both Anaesthetic Methods, Transcatheter Aortic Valve Implantation

Brief summary

Transcatheter aortic valve implantation (TAVI) is an alternative for patients, that are considered to be too sick for conventional aortic valve replacement. There is no conclusive opinion about the best anesthesiologic management of these patients. Sedation and general anaesthesia are both adequate and the current literature shows no benefit towards one of these methods. This study wants to investigate the influence of these two anesthesiologic managements on the cerebral oxygen saturation during the rapid pacing-period during valvuloplasty. The patients are randomised allocated to one of these two anaesthesiological managements. The investigators use the Near-Infrared Spectroscopy (NIRS) to measure the cerebral oxygen saturation. Parallel there will be a measurement of cerebral biomarkers to monitor cerebral hypoxia.

Interventions

PROCEDUREGeneral anaesthesia

general anaesthesia is performed according to the hospitals standard

PROCEDURESedation

Sedation is performed according to the hospitals standard

Sponsors

Deutsches Herzzentrum Muenchen
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* informed consent * transcatheter aortic valve implantation

Exclusion criteria

* denial by patient * denial by screening anaesthesist * active neurodegenerative disease

Design outcomes

Primary

MeasureTime frameDescription
Cerebral oxygen desaturation during the rapid pacing period and periproceduralup to 48 hoursBiomarkers for cerebral ischemia will be measured up to 48 hours

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026